Novel Drug Delivery Strategies That Target Specific Proteins to Promote Effective Therapeutics
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".
Deadline for manuscript submissions: 30 September 2024 | Viewed by 154
Special Issue Editors
Interests: targeted delivery; protein-based nanoparticles; avidin biotin; bioconjugation; PEG chemistry; sol-gel silica; immunodiagnostics
Interests: novel anti-cancer agents; protein modification; drug discovery; disease modeling
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Proteins are involved in various biological processes and pathways that are essential for the normal functioning of cells and tissues. However, when these proteins are dysregulated, mutated, or overexpressed, they can cause or contribute to various diseases, such as cancer, inflammation, infection, neurodegeneration, and metabolic disorders. Therefore, targeting these proteins with specific drugs can modulate their activity and restore the balance of the system.
However, delivering drugs to induce protein degradation/ aggregation, or block their activity is a significant task. There are many challenges and obstacles that need to be overcome, such as the stability, solubility, bioavailability, immunogenicity, toxicity, and specificity of the drugs. Moreover, the drugs need to reach the target site in sufficient concentration and duration to exert their intended therapeutic effect.
In this Special Issue, we invite researchers to submit original research articles and reviews that cover various aspects of novel drug delivery strategies to target specific proteins in diseases. We welcome contributions that address the following topics:
- Molecular design, expression, purification, characterization, safety, and efficacy of drugs aimed to target proteins for therapy;
- Design and development of novel experimental and theoretical methods for drug discovery to target disease-related proteins, with an emphasis on the mechanisms of drug interference with protein-driven biological pathways;
- Peptide-based degraders such as protacs and peptins that can induce the degradation of target proteins by hijacking the ubiquitin-proteasome system or disrupting protein–protein interactions.
We hope that this Special Issue will provide a comprehensive overview of the current state of the art and future directions in targeting proteins to alleviate diseases using drug discovery technology.
Dr. Margherita Morpurgo
Dr. Raj Nayan Sewduth
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
